The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer
Open Access
- 4 December 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 8, 577
Abstract
Introduction: To examined survival outcome by histological subtypes in de novo stage IV epithelial ovarian cancer (EOC). Methods: Between 2004 and 2015, patients with stage IV EOC were included using the Surveillance, Epidemiology, and End Results program. The effects of histological subtypes on overall survival (OS) were assessed using Kaplan–Meier and multivariable Cox regression analyses. Results: We identified 5,953 patients including 5,351 (89.9%), 249 (4.2%), 145 (2.4%), and 208 (3.4%) patients with high-grade serous, endometrioid, mucinous, and clear cell subtypes, respectively. The 5-year OS rates were 28.1, 38.6, 14.2, and 18.8% in patients with high-grade serous, endometrioid, mucinous, and 18.8% clear cell subtypes, respectively, (p < 0.001). Multivariate analyses indicated that histological subtype was an independent predictor of OS. Using the high-grade serous subtype as a reference, OS was comparable for the endometrioid subtype (hazard ratio (HR) 0.915, 95% confidence interval) (CI 0.772–1.085, p = 0.305), but significantly lower for mucinous (HR 3.292, 95% CI 2.701–4.011, p < 0.001) and clear cell subtypes (HR 1.820, 95% CI 1.546–2.141, p < 0.001). Patients with no residual tumor had better OS in the high-grade serous and endometrioid subtypes compared to patients with residual tumors. However, the residual tumor size was not a prognostic factor for OS in mucinous and clear cell carcinoma. Conclusions: Our study suggest a markedly mortality rate in patients with stage IV mucinous and clear cell carcinoma, but better survival in patients with high-grade serous and endometrioid subtypes. Aggressive radical surgery to leave no residual disease would improve survival for high-grade serous and endometrioid carcinoma. More studies are needed to assess the value of aggressive radical surgery in patients with mucinous and clear cell subtypes.Keywords
This publication has 34 references indexed in Scilit:
- Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in TaiwanJournal of Gynecologic Oncology, 2013
- Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgeryInternational Journal of Clinical Oncology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian CancerInternational Journal of Gynecological Cancer, 2010
- Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV DiseaseAnnals of Surgical Oncology, 2010
- Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2008
- Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical stagingBritish Journal of Cancer, 2006
- New tumor markers: CA125 and beyondInternational Journal of Gynecological Cancer, 2005
- Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific TreatmentJournal of Clinical Oncology, 2004
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996